Food Allergy Yardstick Webinar

The landscape of food allergy management has evolved significantly, shifting from strict allergen avoidance to the introduction of targeted immunotherapies. The recent approval of omalizumab, alongside earlier therapies, offers clinicians a range of options to manage IgE-mediated food allergies effectively. The integration of these new treatments into clinical practice requires an understanding of their benefits, risks, and appropriate application within a patient-centered care framework. This webinar presented an overview of the Food Allergy Yardstick, covering patient selection, treatment considerations and shared decision-making and creating appropriate treatment plans. 

Price: FREE for members and non-members
Recorded on: April 16, 2025
Time to complete: 30 minutes

CME is not offered for this activity.

This webinar was supported by a grant from Genentech, A Member of the Roche Group

Additional Resources

Target Audience

Allergy Immunology Specialists, Primary care providers interested in food allergy.

Learning Objectives

After participating in this webinar, participants should be better able to:

  • Appropriately assess food allergy patients for selection of treatment with omalizumab
  • Interpret the treatment options for IgE-mediated food allergy by using the Food Allergy Yardstick
  • Formulate a plan for therapy using SDM with a patient/family with IgE-mediated food allergy
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
04/17/2025
Course expires: 
12/31/2026
Rating: 
0

Aikaterini (Katherine) Anagnostou, MD, MSc, PhD, FACAAI, Professor of Pediatrics, Division of Immunology, Allergy and Retrovirology, Director, Allergy and Food Therapeutics, Lead, Adolescent Transition for Allergy at Texas Children's Hospital & Baylor College of Medicine in Houston, Texas.
Disclosures: Institutional Funding: Novartis, AAFA, Aquestive; Advisor: Ready/Set/Food, Novartis, Bryn; Consultant/Speaker: ALK, EPG Health, MJH, Adelphi, Aimmune Therapeutics, Genentech, Medscape, ARS, FARE, Stallergens

Marcus S. Shaker, MD, MSc, FACAAI, Professor of Pediatrics and Medicine at the Dartmouth Geisel School of Medicine in Hanover, New Hampshire.
Disclosures: Nothing to disclose

Moderator:
James M. Tracy, DO, FACAAI, President of ACAAI, Clinical Professor of Pediatrics at the University of Nebraska in Lincoln, Nebraska.
Disclosures: Advisor: Biocryst, Genentech, KalVista

Non-CME

Please login or create an account to take this course.